Environmental

CLNN’s very high R&D intensity versus revenue suggests a science-led model, but peers in biotech often show similarly elevated research spending, limiting relative environmental differentiation.

The company’s operating footprint is likely lighter than manufacturing-heavy peers, which reduces direct emissions and resource-use exposure, although this advantage is typical for development-stage biopharma.

No disclosed environmental incidents or transition-risk disclosures were provided, so relative positioning remains neutral rather than clearly advantaged versus peers.

Because environmental materiality in this sector is driven more by laboratory energy use, waste handling, and supply-chain controls than by scale, CLNN appears broadly in line with small-cap biotech peers.

Social

Stock-based compensation at 36.2% of revenue indicates heavy reliance on equity incentives, which can support talent retention but also signals dilution pressure versus better-capitalized peers.

The absence of provided workforce, safety, or product-access disclosures limits evidence of stronger social practices, leaving CLNN less transparent than larger peers with fuller reporting.

As a development-stage biotech, social materiality centers on clinical-trial conduct, patient safety, and data integrity, but no peer-leading disclosures were provided here.

Relative to peers, CLNN appears neither structurally advantaged nor severely impaired on social factors, with disclosure depth the main constraint on a stronger score.

Governance

Stock-based compensation at 36.2% of revenue suggests governance pressure around dilution and incentive alignment, which is more acute than at mature peers with lower equity dependence.

Negative leverage metrics indicate a capital structure shaped by losses and financing needs, increasing governance sensitivity to capital allocation discipline versus better-funded peers.

The lack of provided board, audit, or ownership detail prevents evidence of strong governance differentiation, leaving CLNN below peers with more robust disclosure and oversight signals.

Overall governance positioning appears modest because financing dependence and limited transparency outweigh any benefits from a straightforward small-company structure.

Overall Score

CLNN’s ESG positioning is broadly average for a development-stage biotech, with limited disclosure and financing dependence offsetting a relatively light operating footprint.

Score Driver: Limited Governance Transparency And Equity-Financing Dependence Versus Peers